Document is current

Article History

Received: 29 September 2025

Revised: 10 December 2025

Accepted: 17 December 2025

First Online: 6 January 2026

Compliance with ethical standards

:

: The scientific guarantor of this publication is Sungmin Woo.

: The authors of this manuscript declare relationships with the following companies: K.P.F. is a co-investigator on “Optimizing timing of rhPSMA-7.3 (18F), for assessing site(s) of recurrent disease following radical prostatectomy,” but does not receive any salary support and is unrelated to the current work. M.E.M. received honoraria for lectures from Siemens, GE, and BM, but unrelated to the current work. L.K.S. received Honoraria and travel, accommodation, and expenses from Lantheus Medical Imaging and has consulting roles at Roche/Genentech and Point BioPharma. J.S.W. received funding from EDAP, FocalOne, Uro-1 Medical, ExoDx, and Francis Medical. M.P.E. has received advisory board fees from Merck, Eisai, and Aveo Oncology. D.R.W. has received consulting fees from Leap Therapeutics, Foundation Medicine, Pfizer, Janssen, Sanofi, Lilly, Labcorp, Myovant, Bayer, AstraZeneca, Accutar and has received travel funding from Pfizer and Bayer, but unrelated to the current work. M.J.Z. has received honoraria for speaking engagements from Elekta and as a consultant for Boston Scientific. The other authors have nothing to disclose.

: No complex statistical methods were necessary for this paper.

: Written informed consent was waived by the Institutional Review Board.

: Institutional Review Board approval was obtained.

: No overlapping study subjects or cohorts have been previously reported.

: